PHARMAID.BO · BSE
PHARMAIDS PHARMACEUTICALS LTD.
₹30.46
+1.16% (+₹0.35)
Prev. close
₹30.11
Volume
1,677
As of
BSE · may be slightly delayed · 16:01 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About PHARMAIDS PHARMACEUTICALS LTD.
Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides contract research and manufacturing services for pharma, biotech, agro, and chemical industries in India. It provides pharma intermediates, such as Dichloro Benzoyl nitrile, hydrazine carboximidamide 2 methane, pyridine carbonitrile, pyridine carboxylic acid, 8-chloro-10, 11-dihydro-4-aza-5H-dibenzo cycloheptene-5-one, 8-chloro-6,11-dihydro-11 cyclohepta pyridine, 2-amino-5-methylthiopene-3-carbonitrile, 5-methyl-2-amino thiophene-3-carbonitrile, 4-amino-2-methyl-10h-thiene benzodiazepine hydrochloride, 2,4-diamino-6-chloropyrimidine, hydronopol, squalene, 5-chloro-3-phenylanthranil, 2-amino-2,5-dichlorobenzophenone, 6-fluoro-3-4-piperidinyl-1,2-benzisoxazole hcl, 3-2-methyl-4H-pyrido pyrimidin-4-one, 4-n-hexyl resorcinol, triazole kopoxil, CAB-60, CABER-4, CAB-70, DTV, avobenzone, nopol, hydronopol, and narwedine. The company also offers active pharmaceuticals ingredients, including voglibose, silodosin, vitamin K2-7, UDCA, P5P, fluralaner, afoxolaner, maropitant, grapiprant, firocoxib, carprofen, loratadine, desloratadine, lamotrigine, gliclazide, and minoxidil. Pharmaids Pharmaceuticals Limited was incorporated in 1989 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. B.C Balagangadhara
Headquarters
Bengaluru
Employees
127
Website
pharmaids.comExchange
View on BSE ↗Key stats
Market cap
₹106.19 Cr
EPS (TTM)
₹-1.27
Beta (1Y · daily vs NIFTY 50)
0.64
Beta (5Y · monthly vs NIFTY 50)
0.34
Shares float
98.62 L
EPS · quarter ended Jun 2026
₹0.63
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹0 | ₹15.11 Cr | ₹18.81 Cr | ₹27.37 Cr | |
| EBITDA | ₹-9.89 Cr | ₹-12.34 Cr | ₹-12.83 Cr | ₹-11.00 Cr |
| ₹-7.56 Cr | ₹-7.97 Cr | ₹-10.78 Cr | ₹-11.72 Cr | |
| Diluted EPS | ₹-5.86 | ₹-3.56 | ₹-3.05 | ₹-3.31 |
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹24.58 Cr | ₹91.34 Cr | ₹119.85 Cr | ₹87.26 Cr | |
| ₹0 | ₹8.53 Cr | ₹38.97 Cr | ₹23.38 Cr | |
| Stockholders' equity | ₹22.46 Cr | ₹72.05 Cr | ₹59.32 Cr | ₹47.65 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-4.02 Cr | ₹-10.62 Cr | ₹-15.11 Cr | ₹-4.06 Cr | |
| Investing cash flow | ₹-4.94 Cr | ₹-74.99 Cr | ₹-12.22 Cr | ₹23.34 Cr |
| ₹21.31 Cr | ₹77.66 Cr | ₹23.36 Cr | ₹-19.97 Cr | |
| Capital expenditure | ₹-1.67 Cr | ₹-22.86 Cr | ₹-12.48 Cr | ₹-4.47 Cr |
| End cash position | ₹12.75 Cr | ₹4.80 Cr | ₹82.29 L | ₹13.35 L |
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| PHARMAIDS PHARMACEUTICALS LTD. | ₹104.89 Cr | ₹29.74 | — | 2.20 | -24.6% | 0.49 | +45.5% | -47.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.